Skip to main content

Table 2 Clinical characteristics of the patients in the CERTIM NSCLC cohort

From: The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

Characteristic

Category

N (%)

Sex

M

23 (62%)

F

14 (38%)

Age (year)

Median (range)

68 (41–78)

Tumor type

Adenocarcinoma

25 (68%)

Squamous cell carcinoma

10 (27%)

NOS

2 (5%)

Smoking status

Non smoker

4 (11%)

Smokers

33 (88%)

 < 10 pack/year (≤ 10 packs years)

 [10–30] pack/year

19 (57%)

 > 30 pack/year

14 (42%)

 Quit > 1 year

19 (57%)

 Active or quit ≤ 1 year

14 (42%)

ECOG performance status

0

1 (3%)

1

18 (49%)

≥ 2

18 (49%)

Previous lines of therapy

0

1

22 (59%)

2

6 (16%)

≥ 3

9 (24%)

ORR

CR

3 (8%)

PR

4 (11%)

SD

6 (16%)

PD

24 (65%)